News

 

 

Clinical Trials

Alexey V. Danilov
Assistant Professor
Molecular Therapeutics

  • Janssen Research and Development, L.L.C.
    Randomized, double-blind, placebo-controlled Phase 3 study of Ibrutinib, a Bruton`s Tyrosine Kinase (BTK) inhibitor, in combination with Bendamustine and Rituximab (BR)in subjects with relapsed or refractory chronic lymphocytic leukemia/smallLymphocytic lymphoma

Marc Ernstoff
Professor
Immunology and Cancer Immunotherapy

  • Prometheus Laboratories Incorporated, Cytokine Working Group (CWG)
    Inhibiting the systemic autophagic syndrome - A Phase I/II study of hydroxychloroquine and aldesleukin in Renal Cell Carcinoma patients (RCC)